Anavip

Last updated

Anavip
Clinical data
Trade names Anavip
Other names
  • Crotalidae immune F(ab')2 (equine)
  • Viper antivenom
AHFS/Drugs.com Monograph
Legal status
Legal status
Identifiers
PubChem SID
DrugBank
UNII

Anavip is the brand name of a snake antivenin indicated for the management of people with North American rattlesnake envenomation. [3] [4] [1] As defined by the US Food and Drug Administration (FDA), the proper name is crotalidae immune F(ab')2 (equine). [2] It is manufactured by Rare Disease Therapeutics.

Anavip is a divalent fragment antigen-binding protein, F(ab')2, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus . The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')2. [1]

References

  1. 1 2 3 "Anavip crotalidae immune F(ab')2 (equine) Lyophilized Powder for Solution for Injection For Intravenous Use Only" (PDF). Rare Disease Therapeutics. Retrieved 18 August 2020.
  2. 1 2 "Anavip". U.S. Food and Drug Administration (FDA). 1 April 2021. STN: 125488. Retrieved 3 October 2025.
  3. ↑ Cocchio C, Johnson J, Clifton S (January 2020). "Review of North American pit viper antivenoms". American Journal of Health-System Pharmacy. 77 (3): 175–187. doi:10.1093/ajhp/zxz278. PMID   31974558.
  4. ↑ "Marketing authorization with orphan designation - USA". orpha.net. orphanet. Retrieved 19 August 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.